JP Morgan analyst Hardik Parikh reiterated an 'Overweight' rating on Viking Therapeutics but reduced the price target from $75 to $65. This indicates a continued positive outlook on the company's long-term prospects, despite a slightly tempered near-term valuation expectation.
JP Morgan analyst Hardik Parikh maintained an 'Overweight' rating on Viking Therapeutics (VKTX), signaling a continued belief in the company's fundamental strength and future growth potential. However, the price target was lowered from $75 to $65. This adjustment suggests that while the analyst still sees upside, there might be new information or re-evaluation of factors that have slightly reduced the near-term valuation. For traders, this could lead to short-term downward pressure on VKTX's stock as the market digests the lowered price target, despite the maintained 'Overweight' rating. The long-term implications remain positive, but the immediate reaction might be cautious.